ACURA PHARMACEUTICALS, INC

Form 4

August 22, 2007

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

0.5

January 31, Expires: 2005

OMB APPROVAL

Estimated average

burden hours per response...

subject to Section 16. Form 4 or Form 5 obligations

may continue.

See Instruction

if no longer

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * ESSEX WOODLANDS HEALTH VENTURES FUND V LLC

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

Issuer

below)

ACURA PHARMACEUTICALS, INC [ACUR.OB]

(Check all applicable)

(Last)

(First)

(Street)

(Middle)

3. Date of Earliest Transaction

_X__ 10% Owner Director _ Other (specify Officer (give title

(Month/Day/Year)

21 WATERWAY AVENUE, SUITE 08/20/2007

225

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check

Filed(Month/Day/Year) Applicable Line)

Form filed by One Reporting Person _X_ Form filed by More than One Reporting

Person

THE WOODLANDS, TX 77380

(City)	(State)	(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities A oper Disposed of (Instr. 3, 4 and Amount	(D)	d (A)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
Common Stock							1,361,781	I	subsidiary (1)				
Common stock	08/20/2007		P	33,333,332	A	(2)	34,695,113	I	By subsidiary (3)				
Common Stock	08/20/2007		P	38,125,924	A	<u>(4)</u>	72,821,037	I	By subsidiary (3)				

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Instr. 8	3)	5. Number of or Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securition (Instr. 3 and 4)	
				Code '	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amou Numb Shares
Common Stock Warrants (right to buy)	\$ 0.34							05/08/2003	05/08/2010	Common Stock	345
Common Stock Warrants (right to buy)	\$ 0.34	08/20/2007		P		8,333,333		08/20/2007	08/20/2014	Common Stock	8,33
Common Stock Warrants (right to buy)	\$ 0.34	08/20/2007		P		9,531,481		08/20/2007	08/20/2014	Common Stock	9,53

Reporting Owners

Reporting Owner Name / Address	Relationships					
1	Director	10% Owner	Officer	Other		
ESSEX WOODLANDS HEALTH VENTURES FUND V LLC 21 WATERWAY AVENUE, SUITE 225 THE WOODLANDS, TX 77380		X				
ESSEX WOODLANDS HEALTH VENTURES FUND V LP 21 WATERWAY AVENUE, SUITE 225 THE WOODLANDS, TX 77380		X				

Signatures

/s/ Dennis Peterson, Attorney-in-fact

08/22/2007

**Signature of Reporting Person

Date

Reporting Owners 2

Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 4

/s/ Dennis Peterson, Attorney-in-fact for Essex Woodlands Health Ventures Fund V, LLC, its general partner

08/22/2007

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The Reporting Person, as general partner of Essex Woodlands Health Ventures Fund V, L.P., the direct owner of the reported securities, beneficially owns the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
- (2) The reported securities are included within 8,333,333 Units of Acura Pharmaceuticals, Inc. purchased by GCE Holdings LLC for \$1.08 per Unit.
 - The Reporting Person, as general partner of Essex Woodlands Health Ventures Fund V, L.P., which is a member of GCE Holdings LLC,
- (3) the direct owner of the reported securities, beneficially owns the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
 - The reported securities are included within 9,531,481 Units of Acura Pharmaceuticals, Inc. received by GCE Holdings LLC in
- (4) satisfaction of the outstanding aggregate of \$10.294 million in principal amount under Acura Pharmaceuticals, Inc.'s outstanding bridge loan indebtedness.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3